156 related articles for article (PubMed ID: 29339319)
1. Treatment with the noradrenaline re-uptake inhibitor atomoxetine alone and in combination with the α2-adrenoceptor antagonist idazoxan attenuates loss of dopamine and associated motor deficits in the LPS inflammatory rat model of Parkinson's disease.
Yssel JD; O'Neill E; Nolan YM; Connor TJ; Harkin A
Brain Behav Immun; 2018 Mar; 69():456-469. PubMed ID: 29339319
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological targeting of β
O'Neill E; Yssel JD; McNamara C; Harkin A
Br J Pharmacol; 2020 Jan; 177(2):282-297. PubMed ID: 31506926
[TBL] [Abstract][Full Text] [Related]
3. Blockade of α2-adrenergic receptors in prelimbic cortex: impact on cocaine self-administration in adult spontaneously hypertensive rats following adolescent atomoxetine treatment.
Baskin BM; Nic Dhonnchadha BÁ; Dwoskin LP; Kantak KM
Psychopharmacology (Berl); 2017 Oct; 234(19):2897-2909. PubMed ID: 28730282
[TBL] [Abstract][Full Text] [Related]
4. Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
Srinivasan J; Schmidt WJ
Behav Brain Res; 2004 Oct; 154(2):353-63. PubMed ID: 15313023
[TBL] [Abstract][Full Text] [Related]
5. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Alam M; Danysz W; Schmidt WJ; Dekundy A
Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effects of garlic extract on dopaminergic neurons of substantia nigra in a rat model of Parkinson's disease: motor and non-motor outcomes.
Bigham M; Mohammadipour A; Hosseini M; Malvandi AM; Ebrahimzadeh-Bideskan A
Metab Brain Dis; 2021 Jun; 36(5):927-937. PubMed ID: 33656625
[TBL] [Abstract][Full Text] [Related]
7. Contrasting Roles of Dopamine and Noradrenaline in the Motivational Properties of Social Play Behavior in Rats.
Achterberg EJ; van Kerkhof LW; Servadio M; van Swieten MM; Houwing DJ; Aalderink M; Driel NV; Trezza V; Vanderschuren LJ
Neuropsychopharmacology; 2016 Feb; 41(3):858-68. PubMed ID: 26174597
[TBL] [Abstract][Full Text] [Related]
8. Galangin Reduces the Loss of Dopaminergic Neurons in an LPS-Evoked Model of Parkinson's Disease in Rats.
Chen G; Liu J; Jiang L; Ran X; He D; Li Y; Huang B; Wang W; Fu S
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29267220
[TBL] [Abstract][Full Text] [Related]
9. GPER activation is effective in protecting against inflammation-induced nigral dopaminergic loss and motor function impairment.
Mendes-Oliveira J; Lopes Campos F; Videira RA; Baltazar G
Brain Behav Immun; 2017 Aug; 64():296-307. PubMed ID: 28450223
[TBL] [Abstract][Full Text] [Related]
10. Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.
Srinivasan J; Schmidt WJ
J Neural Transm (Vienna); 2005 Sep; 112(9):1223-36. PubMed ID: 15614426
[TBL] [Abstract][Full Text] [Related]
11. Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease.
Hansen HH; Fabricius K; Barkholt P; Mikkelsen JD; Jelsing J; Pyke C; Knudsen LB; Vrang N
Brain Res; 2016 Sep; 1646():354-365. PubMed ID: 27233809
[TBL] [Abstract][Full Text] [Related]
12. AAV2-mediated striatum delivery of human CDNF prevents the deterioration of midbrain dopamine neurons in a 6-hydroxydopamine induced parkinsonian rat model.
Ren X; Zhang T; Gong X; Hu G; Ding W; Wang X
Exp Neurol; 2013 Oct; 248():148-56. PubMed ID: 23764500
[TBL] [Abstract][Full Text] [Related]
13. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
14. Atomoxetine restores the response inhibition network in Parkinson's disease.
Rae CL; Nombela C; Rodríguez PV; Ye Z; Hughes LE; Jones PS; Ham T; Rittman T; Coyle-Gilchrist I; Regenthal R; Sahakian BJ; Barker RA; Robbins TW; Rowe JB
Brain; 2016 Aug; 139(Pt 8):2235-48. PubMed ID: 27343257
[TBL] [Abstract][Full Text] [Related]
15. Amphetamine and cocaine suppress social play behavior in rats through distinct mechanisms.
Achterberg EJ; Trezza V; Siviy SM; Schrama L; Schoffelmeer AN; Vanderschuren LJ
Psychopharmacology (Berl); 2014 Apr; 231(8):1503-15. PubMed ID: 24057815
[TBL] [Abstract][Full Text] [Related]
16. α-Asarone attenuates microglia-mediated neuroinflammation by inhibiting NF kappa B activation and mitigates MPTP-induced behavioral deficits in a mouse model of Parkinson's disease.
Kim BW; Koppula S; Kumar H; Park JY; Kim IW; More SV; Kim IS; Han SD; Kim SK; Yoon SH; Choi DK
Neuropharmacology; 2015 Oct; 97():46-57. PubMed ID: 25983275
[TBL] [Abstract][Full Text] [Related]
17. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.
Dominguez-Meijide A; Villar-Cheda B; Garrido-Gil P; Sierrra-Paredes G; Guerra MJ; Labandeira-Garcia JL
Neuropharmacology; 2014 Jan; 76 Pt A():156-68. PubMed ID: 23973568
[TBL] [Abstract][Full Text] [Related]
18. Noradrenaline acting at central beta-adrenoceptors induces interleukin-10 and suppressor of cytokine signaling-3 expression in rat brain: implications for neurodegeneration.
McNamee EN; Ryan KM; Griffin EW; González-Reyes RE; Ryan KJ; Harkin A; Connor TJ
Brain Behav Immun; 2010 May; 24(4):660-71. PubMed ID: 20193756
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
20. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the α5 nicotinic acetylcholine receptor subunit.
Leino S; Koski SK; Hänninen R; Tapanainen T; Rannanpää S; Salminen O
Neuropharmacology; 2018 Aug; 138():371-380. PubMed ID: 29940207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
